Clinical Trials

Currently Enrolling | Ongoing, Enrollment Complete | Completed Trials

Clinical Trials Currently Enrolling

 Please contact the individual trial centers listed below for enrollment information. You may also click on the clinicaltrials.gov link for specific trial information.
Product Candidate Location Principal Investigator Indication Phase Contact
MKC-1
clinicaltrials.gov		Princess Margaret HospitalDr. Karen YeeLeukemiaIDr. Karen Yee
416-946-4495
MKC-1 with Pemetrexed
clinicaltrials.gov		Multi-Center TrialDr. Nasser H. HannaAdvanced Cancer and Non-Small Cell Lung Cancer (NSCLC)I / IIDeborah Estes, R.N.
(317) 278-6599
ENMD-1198 University of Colorado Cancer Center, Aurora, CODr. Ross CamidgeAdvanced CancerIMary Kay Schultz
(720) 848-0376 or
Sharon VanDoren
(720) 848-1543
MKC-1 Multi-centerDr. Eunice KwakPancreatic CancerIISusan Sheehan 617-724-9347 phone / 617-724-2840 fax
MKC-1 Multi-centerDr. Amit OzaOvarian/Endometrial CancersIIDr. Amit Oza
Tel: 416-946-2818
MKC-1 University of WisconsinGlenn Liu, M.D.Advanced CancerICancer Connect (800) 622-8922
ENMD-2076 University of Colorado and Dana-Farber Cancer InstituteDr. Wells Messersmith & Dr. Geoffrey ShaprioAdvanced CancersIUniversity of Colorado, Stacy Grolnic, RN (720) 848-0655
Dana Farber Cancer Institute, Pilar de la Rocha (617) 632-5841

Ongoing Trials, Enrollment Closed
Product Candidate Location Principal Investigator Indication Phase
Panzem® NCD w/ Temodar®Preston Robert Tisch Brain Tumor Center at Duke University Medical CenterDr. Annick DesjardinsGlioblastoma Multiforme (GBM)II
Panzem® NCDMulti-Center TrialDr. Glenn LiuRenal Cell CarcinomaII
Panzem® NCDMulti-Center TrialDr. Glenn LiuHormone-Refractory Prostate CancerII
MKC-1Multi-Center TrialAdvanced and Metastatic Breast CancerII
Panzem® NCDDuke University Medical CenterDr. Kimberly L. BlackwellMetastatic Breast CancerIb
Panzem® NCDIndiana University Cancer Center, Indianapolis, INDr. Christopher J. SweeneyAdvanced CancerIb (Part B)
Panzem® NCDDana-Farber Cancer Institute, Boston, MassachusettsDr. Matthew KulkeCarcinoid CancerII
Panzem® NCDMulti-Center TrialDr. Daniela E. MateiOvarian CancerII
Panzem® NCDBrain Tumor Center at Duke University Medical Center, Durham, NCDr. David A. ReardonBrain CancerII
Panzem® CapsulesMayo Clinic, Rochester, MNDr. Vincent RajkumarMultiple MyelomaII
Panzem® CapsulesDana-Farber Cancer Institute, Boston, MADr. Paul RichardsonMultiple MyelomaII

Completed Trials
Product Candidate Location Principal Investigator Indication Phase
Panzem® NCD University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison, WIDr. George WildingAdvanced CancerIb (Part B)
Panzem® NCD University of Wisconsin Comprehensive Cancer Center (UWCCC), Madison, WIDr. George WildingAdvanced CancerIb (Part A)
Panzem® NCD Indiana University Cancer Center, Indianapolis, INDr. Christopher J. SweeneyAdvanced CancerIb (Part A)
Panzem® Capsules *National Cancer Institute, Bethesda, MDDr. William D. Figg, Dr. William DahutAdvanced Solid TumorsI
Panzem® Capsules **Mayo Clinic, Rochester, MNDr. Charles ErlichmanAdvanced Solid TumorsI
Panzem® Capsules University of Wisconsin, Madison, WI Dr. George WildingProstate CancerII
Panzem® Capsules Indiana University Cancer Center, Indianapolis, INDr. Chris Sweeney, Dr. George SledgeProstate CancerII
Panzem® Capsules Indiana University Cancer Center, Indianapolis, INDr. Kathy Miller , Dr. George SledgeMetastatic Breast CancerI
Panzem® Capsules w/ Taxotere® Indiana University Cancer Center, Indianapolis, INDr. Kathy Miller , Dr. George SledgeMetastatic Breast CancerI
* NCI-sponsored trial. EntreMed provided only the study drug for this trial.
** NCI-sponsored trial. EntreMed provided only the study drug for this trial.